NeoGenomics Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012 Provides Financial Outlook for 2013 PR Newswire FT. MYERS, Fla., Feb. 14, 2013 FT. MYERS, Fla., Feb. 14, 2013 /PRNewswire/ --NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year 2012. Fiscal Year 2012 Highlights: o50% Test Volume Growth o38% Revenue Growth o181% Increase in Adjusted EBITDA oNet Income of $65K, or $0.00 per Share Revenue for the full year 2012 was $59.9 million, a $16.4 million or 38% increase over 2011 revenue of $43.5 million on test volume growth of 50%. Average revenue-per-test decreased by 8% as a result of the expiration of the TC Grandfather Clause on June 30th, which resulted in the loss of approximately $2.6 million of revenue in the second half of the year. Despite this major regulatory change, gross margin improved slightly to 44.8% on a full-year basis from 44.7% in 2011. Total operating expenses increased by 29% from 2011, primarily as a result of a $1.7 million increase in R&D expenditures related to new test development, as well as increased personnel, depreciation and bad debt expense associated with the revenue growth. As a percentage of revenue, operating expenses improved to 42.8% in 2012 from 45.6% in 2011. Net income for 2012 was $65,000 or $0.00 per share versus a net loss of $1.2 million or ($0.03) per share in 2011. Adjusted EBITDA for the year improved by $3.9 million or 181% to $6.0 million from $2.1 million in 2011. Fourth Quarter 2012 Highlights: o35% Test Volume Growth o16% Revenue Growth o36% Increase in Adjusted EBITDA oNet Loss of $113K, or ($0.00) per Share Revenue for the fourth quarter 2012 was $14.9 million, a $2.0 million or 16% increase over fourth quarter 2011 revenue on test volume growth of 35%. Gross profit increased to $6.5 million, a 10% increase from the fourth quarter 2011. Total operating expenses increased by $780,000 or 14% from last year's fourth quarter, primarily as a result of a $320,000 increase in R&D expenditures related to new test development and increased personnel and depreciation expense. Net loss for the quarter was ($113,000), or ($0.00) per share, versus net income of 152,000, or $0.00 per share in last year's fourth quarter. Adjusted EBITDA improved 36% to $1.4 million versus $1.1 million in the prior year. Douglas M. VanOort, the Company's Chairman and CEO commented, "We are very proud of our full-year 2012 results. Our industry-leading 50% growth in test volume indicates that we are clearly winning market share. Although the TC Grandfather expiration reduced revenue by $2.6 million in the second half of the year, we were still able to increase revenue by $16 million or 38% versus 2011 with just 18 sales representatives. As importantly, productivity and process improvements allowed us to grow Adjusted EBITDA by 181% versus 2011, or almost five times the revenue growth rate, and post a modest profit for the year. Our team did a phenomenal job of delivering outstanding service, attracting new clients, reducing costs, and introducing important new tests. We believe we can continue to make progress in each of these important areas in 2013." Mr. VanOort continued, "We are also proud of our 4^th quarter results. We continued to make substantial improvements in lab productivity and operating efficiency in the quarter and came very close to returning to quarterly profitability. Lab productivity increased by 15% and Adjusted EBITDA grew by 36% from last year's fourth quarter. The improvements were also significant compared with Quarter 3, 2012 as we reduced our net loss by $800,000 with only a $700,000 increase in revenue." Mr. VanOort concluded, "We are particularly proud of the level of innovation and new test development that we are accomplishing. In 2012, we introduced 29 new molecular tests, most of which use bi-directional Sanger sequencing, and built our molecular test menu to be one of the most comprehensive in the lab industry. We also launched 10-color flow cytometry and became the first lab in the country to offer this exciting new service on both a global and tech-only basis. In addition, we vastly improved our immunohistochemistry offering with dozens of new antibodies and brought up a new digital imaging platform. We also continued to expand our comprehensive FISH menu with several new test offerings including a promising new test to aid in the diagnosis of Barrett's Esophagus. We expect these new tests to drive substantial growth in 2013, and we expect that continued R&D investments will result in the commercialization of a number of new and innovative genetic tests." 2013 Financial Outlook The Company also issued preliminary guidance for the full year and fiscal first quarter of 2013 today. For the full year 2013, the Company expects revenue of $68 - $73 million and net income of $0.03 - $0.05 per share. For the fiscal first quarter, the Company expects revenue of $15.3 - $16.0 million and net income of $0.00 to $0.01 per share. This guidance is based on organic growth in the current business and is based on the assumption that there will be no material reimbursement changes during the balance of 2013. The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance. ____________________ Adjusted EBITDA is defined as earnings before interest, taxes, depreciation, amortization, other extraordinary or non-recurring charges, such as the costs related to moving our California facility and non-cash stock-based compensation expenses. See table for a reconciliation to net income. Conference Call The Company has scheduled a web-cast and conference call to discuss their Q4 and full year 2012 results on February 14, 2013 at 11:00 AM EST. Interested investors should dial (800) 374-1317 (domestic) and (404) 665-9940 (international) at least five minutes prior to the call and ask for Conference ID 97486925. An archive of the conference call will be available at https://us.reg.meeting-stream.com/neogenomicsinc_021413/ for a period of one year from the date of the conference call. The web-cast may be accessed on the homepage of our website at http://www.neogenomics.com or https://us.reg.meeting-stream.com/neogenomicsinc_021413/. About NeoGenomics, Inc. NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com. Interested parties can also access investor relations material from Hawk Associates at http://www.hawkassociates.com or firstname.lastname@example.org and from Zack's Investment Research at http://www.zacks.com or email@example.com. Forward Looking Statements Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC. NeoGenomics, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, in thousands) ASSETS December 31, December 31, 2012 2011 Cash, cash equivalents $ 1,868 $ 2,628 Restricted Cash - 500 Accounts Receivable (net of allowance for doubtful 14,034 7,894 accounts of $3,002 and $2,150, respectively) Other Current Assets 2,679 2,156 TOTAL CURRENT ASSETS 18,581 13,178 PROPERTY AND EQUIPMENT (net of accumulated 8,607 6,642 depreciation of $10,289 and $6,653, respectively) INTANGIBLE ASSETS (net of accumulated amortization 2,800 - of $182 and $-, respectively) OTHER ASSETS 83 129 TOTAL $ 30,071 $ 19,949 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES $ 17,758 $ 11,444 LONG TERM LIABILITIES 3,097 2,608 TOTAL LIABILITIES 20,855 14,052 STOCKHOLDERS' EQUITY 9,216 5,897 TOTAL $ 30,071 $ 19,949 NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) For the Twelve-Months For the Three-Months Ended Ended December 31, December 31, 2012 2011 2012 2011 NET REVENUE $ 14,893 $ 12,893 $ 59,867 $ 43,484 COST OF REVENUE 8,460 7,060 33,031 24,056 GROSS PROFIT 6,433 5,833 26,836 19,428 OPERATING EXPENSES General and 4,097 3,530 15,843 12,331 administrative Research and development 448 128 2,281 543 Sales and marketing 1,692 1,800 7,501 6,963 Total operating 6,237 5,458 25,625 19,837 expenses INCOME (LOSS) FROM 196 375 1,211 (409) OPERATIONS INTEREST AND OTHER (309) (223) (1,146) (768) INCOME (EXPENSE) - NET NET INCOME (LOSS) BEFORE (113) 152 65 (1,177) TAXES INCOME TAXES - - - - NET INCOME (LOSS) $ (113) $ 152 $ 65 $ (1,177) NET INCOME (LOSS) PER SHARE $ (0.00) $ 0.00 $ 0.00 $ (0.03) - Basic - Diluted $ (0.00) $ 0.00 $ 0.00 $ (0.03) WEIGHTED AVG NUMBER OF SHARES OUTSTANDING 45,273 43,104 45,027 42,758 - Basic - Diluted 45,273 45,270 48,715 42,758 NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, in thousands) For the For the Year Ended Year Ended December 31, December 31, 2012 2011 NET CASH (USED) IN OPERATING ACTIVITIES $ (492) $ 69 NET CASH (USED) IN INVESTING ACTIVITIES (3,652) (897) NET CASH PROVIDED BY FINANCING ACTIVITIES 3,384 2,359 NET INCREASE (DECREASE) IN CASH AND CASH (760) 1,531 EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 2,628 1,097 CASH AND CASH EQUIVALENTS, END OF PERIOD $ 1,868 $ 2,628 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid $ 1,108 $ 735 SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Purchase of licenses $ 1,945 $ 0 Equipment leased under capital lease and $ 2,782 $ 2,950 equipment loans NeoGenomics, Inc. RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP EBITDA AND ADJUSTED EBITDA (Unaudited, in thousands) For the Three-Months Ended For the Years Ended December 31, December 31, 2012 2011 2012 2011 Net income (loss) (Per $ (113) $ 152 $ 65 $ (1,177) GAAP) Adjustments to Net Loss: Interest expense 309 223 1,146 768 (income), net Amortization of 56 - 182 - intangibles Depreciation 1,088 601 3,637 2,086 EBITDA 1,340 976 5,030 1,677 Further Adjustments to EBITDA: - - 170 - Other non-recurring items Non-cash stock-based 99 79 798 457 compensation Adjusted EBITDA (non-GAAP) $ 1,439 $ 1,055 $ 5,998 $ 2,134 Non – GAAP Adjusted EBITDA Definition "Adjusted EBITDA" is defined by NeoGenomics as net income (loss) from continuing operations before (i) interest expense, (ii) tax expense and therapeutic discovery tax grants, (iii) depreciation and amortization expense, (iv) non-cash stock-based compensation and warrant amortization expense and (v) other extraordinary or non-recurring charges, such as the costs related to moving our California facility. NeoGenomics believes that Adjusted EBITDA provides a more consistent measurement of operating performance and trends across reporting periods by excluding these cash and non-cash items of expense not directly related to ongoing operations from income. Adjusted EBITDA also assists investors in performing analysis that is consistent with financial models developed by research analysts. Adjusted EBITDA as defined by NeoGenomics is not a measurement under GAAP and may differ from non-GAAP measures used by other companies. There are limitations inherent in non-GAAP financial measures such as Adjusted EBITDA because they exclude a variety of charges and credits that are required to be included in a GAAP presentation, and do not therefore present the full measure of NeoGenomics recorded costs against its net revenue. Accordingly, investors should consider non-GAAP results together with GAAP results in analyzing NeoGenomics financial performance. NeoGenomics, Inc. Supplemental Information on Customer Requisitions Received and Tests Performed (Unaudited, in thousands, except test and requisition data) For the Three-Months For the For the For the Ended Three-Months Year Nine-Months December 31, Ended % Inc % Inc 2012 (Dec) Ended Ended (Dec) December 31, 2011 December December 31, 31, 2012 2011 Requisitions Rec'd 19,971 14,240 40.2% 73,773 49,235 49.8% (cases) Number of Tests 30,513 22,557 35.3% 114,606 76,288 50.2% Performed Avg. # of Tests / 1.53 1.58 (3.5%) 1.55 1.55 0.3% Requisition Total Testing $ 14,893 $ 12,893 15.5% $ $ 43,484 37.7% Revenue 59,867 Avg $ 745.74 $ 905.43 (17.6)% $ 811.50 $ 883.20 (8.1)% Revenue/Requisition Avg Revenue/Test $ 488.09 $ 571.59 (14.6)% $ 522.37 $ 570.00 (8.4)% SOURCE NeoGenomics, Inc. Website: http://www.neogenomics.org Contact: Steven C. Jones, Director of Investor Relations of NeoGenomics, Inc., +1-239-325-2001, firstname.lastname@example.org; or Ms. Julie Marshall of Hawk Associates, Inc., +1-305-451-1888, email@example.com
NeoGenomics Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012
Press spacebar to pause and continue. Press esc to stop.